Roche Launches Axelios 1 to Challenge Illumina NGS

Roche has launched the Axelios 1 next-generation sequencing platform, escalating its long-signalled challenge to Illumina in the estimated $7.3 billion global gene sequencing market. Confirmed on 30 June 2026, the platform builds on Roche’s Sequencing by Expansion (SBX) technology, first previewed in February 2026 at a genome science conference, and arrives with initial collaborations at leading genomics institutions including Amsterdam-based Hartwig Medical Foundation and Broad Clinical Labs.

The SBX approach converts DNA or RNA information into a longer, expanded molecule, addressing several performance limitations in current sequencing technology. Roche has positioned the platform on accuracy, scalability and faster speed, arguing that combined with cost efficiency this will enable applications that were previously impractical. Axelios 1 is a high-throughput platform designed to handle both small-scale studies and massive genomic projects from a single instrument, with proof-of-principle work on whole genome sequencing and single-cell RNA sequencing under way since the technology was first unveiled in early 2025.

Matt Sause, Roche Diagnostics CEO, described Axelios as a disruptive technology, with early user applications spanning oncology, genetics and infectious diseases. Analysts are more cautious. J.P. Morgan noted that while there is general intrigue in the SBX category, Illumina’s clinical customer base is sticky and management teams transitioning to the incumbent’s NovaSeq X are not urgently planning to switch. Roche, which more than a decade ago made a hostile bid for Illumina, is now attempting the same outcome by other means.

The commercial question is not whether the SBX architecture works, but whether it works well enough to overcome Illumina’s installed base and clinical workflow lock-in. Roche’s positioning within diagnostics and its wider pathology and companion diagnostics ecosystem gives it a routes-to-market angle Illumina alone cannot match, particularly as clinical NGS use cases continue to expand.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Albert Baines today!